The method of pyrimidine ring fusion at the [c] side of benzothiazines based on the reaction of their chloroaldehyde derivatives with amidines is described. Formation of the structural isomers of reaction products was investigated, and regioselectivity of heterocyclization reactions was shown. A number of novel pyrimidobenzothiazines were synthesized. J. Heterocyclic Chem., 2010.
描述了基于苯并噻嗪的氯醛衍生物与am的反应在嘧啶环的[ c ]侧进行嘧啶环稠合的方法。研究了反应产物的结构异构体的形成,并显示了杂环化反应的区域选择性。合成了许多新颖的嘧啶并苯并噻嗪。J.杂环化学.2010。
2-Amino-quinazolin-5-ones
申请人:Bellamacina R. Cornelia
公开号:US20070027150A1
公开(公告)日:2007-02-01
2-Amino-quinazolin-5-one compounds, stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-quinazolin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the 2-amino-quinazolin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cell proliferative diseases.
Neurologically-active heterocyclic compounds comprising two fused 6-membered rings with nitrogen atoms at positions 1 and 3, a carboxy group at position 4,and a hydroxy group at position 8, with one ring being aromatic. Processes for the preparation of these compounds and their use as pharmaceutical or veterinary agents, in particular for the treatment of neurological conditions, and more specifically neurodegenerative conditions such as Alzheimer's disease.
Substituted quinazoline derivatives for use in gastrointestinal diseases
申请人:Smithkline Beecham Intercredit B.V.
公开号:US05064833A1
公开(公告)日:1991-11-12
2,4-diaminoquinazoline compounds are inhibitors of the H.sup.+ K.sup.+ ATPase enzyme and useful for the treatment of diseases of the stomach based on excessive gastric acid secretion. A compound of the invention is 2-[2-methyl-4-fluorophenyl)amino]-4-(N-methylphenylamino)quinazoline.
The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D]pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.